rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

CDT Equity Inc.

CDT · Nasdaq

Health CareBiotechnologyNot moving yet

CDT stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 99.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$5.9M
Officials’ trades on record
0
Institutions holding
7 (+5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$5.7M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 3
WhoDidSharesTraded
Andrew ReganChief Executive Officersold29028 Aug 2026filed 2 Sep 2026
Mark Andrew Taylor10% ownersold5,000at $0.705218 Jun 2026filed 23 Jun 2026
Mark Andrew Taylor10% ownersold1,464,711at $1.4418 Jun 2026filed 23 Jun 2026
Mark Andrew Taylor10% ownersold5,000at $0.75118 Jun 2026filed 23 Jun 2026
Mark Andrew Taylor10% ownersold593,289at $1.4018 Jun 2026filed 23 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders7+5 on the quarter
New · exited6 · 1
Reported value$80K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
JANE STREET GROUP, LLCnew · filed 14 Aug 202661,190$34K+61,190
CITADEL ADVISORS LLCnew · filed 14 Aug 202632,295$18K+32,295
GEODE CAPITAL MANAGEMENT, LLCnew · filed 12 Aug 202616,739$9,373+16,739
XTX Topco Ltdnew · filed 14 Aug 202612,916$7,233+12,916
Financial Management Professionals, Inc.new · filed 9 Jul 202610,005$5,603+10,005
Tower Research Capital LLC (TRC)added · filed 11 Aug 20269,095$5,093+8,985+8168.2%
Caitong International Asset Management Co., Ltdnew · filed 5 Aug 20261$1+1
30 Sep 2025 – 30 Jun 2026
158Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Andrew Regan Company insiderChief Executive Officer · last 28 Aug 20260 · 1
Mark Andrew Taylor Company insider10% owner · last 18 Jun 20260 · 1
Prospect Capital Securities Ltd Company insider10% owner · last 18 Jun 20260 · 1
Chele Chiavacci Farley Company insiderDirector · last 19 Feb 20260 · 0
Corvus Capital Ltd. Company insider10% owner · last 8 Dec 20250 · 9
James Bligh Company insiderCFO · last 19 Sep 20250 · 0
Freda C. Lewis-Hall Company insiderDirector · last 12 Aug 20250 · 0
Simon Jeremy Fry Company insiderDirector · last 12 Aug 20250 · 0
Faith L. Charles Company insiderDirector · last 16 Apr 20250 · 0
David Tapolczay Company insiderChief Executive Officer · last 18 Nov 20240 · 0
Dovet Ltd Company insider10% owner · last 7 Oct 20240 · 3
Rowland Master Trust Company insider10% owner · last 2 Oct 20240 · 3

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Cash and equivalentsFY 2025 · to 31 Dec 2025$1.5M
Free cash flowFY 2024 · to 31 Dec 2024−$9.7M

Analyst forecasts

No analyst forecasts yet.